NEW YORK, Jan. 8-The West Virginian firm Protea Biosciences has struck a deal with Novartis to identify novel protein biomarkers for cancer, the company said today.
Researchers at the company will apply its proprietary "ultrasensitive" mass spectrometry technique to analyze and identify proteins associated with cancer.
Protea, which says it is the first biotech company in the state, was founded to commercialize technology developed at West Virginia University and the university's Health Sciences Center.
Details of the agreement were not released.
For further information about the company, see its website.